WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017055395) ANTI-CD3XROB04 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/055395 International Application No.: PCT/EP2016/073178
Publication Date: 06.04.2017 International Filing Date: 29.09.2016
IPC:
C07K 16/28 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01) ,C07K 16/46 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46
Hybrid immunoglobulins
Applicants: F. HOFFMANN-LA ROCHE AG[CH/CH]; Grenzacherstrasse 124 4070 Basel, CH (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IR, IS, IT, JP, KE, KG, KM, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
HOFFMANN-LA ROCHE INC.[US/US]; Overlook at Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department Little Falls, New Jersey 07424, US (US)
Inventors: AST, Oliver; CH
BACAC, Marina; CH
BAUER, Sabine; DE
IMHOF-JUNG, Sabine; DE
KLEIN, Christian; CH
KLOSTERMANN, Stefan; DE
MOLHOJ, Michael; DE
MOSER, Samuel; CH
NEUMANN, Christiane; CH
REGULA, Joerg Thomas; DE
SCHAEFER, Wolfgang; DE
UMAÑA, Pablo; CH
WEINZIERL, Tina; CH
Agent: CUENI, Leah; CH
Priority Data:
15188266.902.10.2015EP
Title (EN) ANTI-CD3XROB04 BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
(FR) MOLÉCULES BISPÉCIFIQUES DE LIAISON À L'ANTIGÈNE ACTIVANT LES LYMPHOCYTES T ANTI-CD3XROB04
Abstract:
(EN) The present invention generally relates to bispecific antigen binding molecules for activating T cells, more particularly bispecific antigen binding molecules for activating T cells targeting the Robo 4 receptor. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. In addition, the invention also relates to antibodies that specifically bind to Robo 4.
(FR) La présente invention concerne d'une manière générale des molécules bispécifiques de liaison à l'antigène destinées à activer leslymphocytes T, plus particulièrement des molécules bispécifiques de liaison à l'antigène destinées à activer les lymphocytes T ciblant le récepteur Robo 4. De plus, la présente invention concerne des polynucléotides codant pour ces molécules bispécifiques de liaison à l'antigène, ainsi que des vecteurs et des cellules hôtes comprenant ces polynucléotides. L'invention concerne par ailleurs des procédés de production des molécules bispécifiques de liaison à l'antigène de l'invention, et des procédés d'utilisation de ces molécules bispécifiques de liaison à l'antigène dans le traitement de maladies. En outre, l'invention concerne également des anticorps qui se lient spécifiquement à Robo 4.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)